Related Experiment Video
Updated: May 14, 2026

06:21
Osmotic Minipump Implantation for Increasing Glucose Concentration in Mouse Cerebrospinal Fluid
Published on: April 7, 2023
Fructose Intake Is Associated with Brain Metabolic Reprogramming and Exacerbation of Alzheimer-like Alterations in
Paulina Ormazabal1, Patricio Órdenes-Constenla2, Camila Gherardelli3
1Facultad de Ciencias para el Cuidado de la Salud, Universidad San Sebastián, Lota 2465, Providencia, Santiago 8420524, Chile.
International Journal of Molecular Sciences
|May 13, 2026
Summary
Dietary fructose consumption worsens Alzheimer
Area of Science:
- Neuroscience
- Metabolic Research
- Alzheimer's Disease Pathogenesis
Background:
- Metabolic dysfunction is increasingly linked to Alzheimer's disease (AD).
- The specific effects of dietary fructose on brain function in AD are not well understood.
- Fructose is a common dietary component that causes systemic metabolic changes.
Purpose of the Study:
- To investigate the impact of short-term fructose consumption on metabolism, brain glucose handling, and cognition in a mouse model of AD.
- To explore the relationship between fructose intake, metabolic syndrome markers, and Alzheimer's-like pathology.
Main Methods:
- APP/PS1 transgenic mice were given 15% fructose in drinking water for eight weeks.
- Systemic metabolic parameters (fasting glucose, lipids) were measured.
- Cerebral glucose utilization, amyloid-beta (Aβ42) accumulation, cognitive function, and neuroinflammation markers were assessed.
Main Results:
- Fructose consumption led to metabolic syndrome indicators, including hyperglycemia and dyslipidemia.
- Reduced brain glucose metabolism and increased Aβ42 deposition were observed in fructose-fed mice.
- Cognitive performance declined, and neuroinflammatory markers were elevated.
Conclusions:
- Dietary fructose exacerbates Alzheimer's-like pathology by disrupting brain glucose metabolism and promoting neuroinflammation.
- Fructose intake may represent a modifiable risk factor contributing to Alzheimer's disease vulnerability.
- These findings highlight the link between systemic metabolic health and brain function in AD.
Related Concept Videos
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Gut-Brain Axis
The gut–brain axis is a bidirectional communication system that connects the gastrointestinal tract and the brain. This interaction is mediated through multiple pathways, including the vagus nerve, hormonal signals, immune responses, and chemical messengers produced by gut microbes.Microbial Contributions to Brain FunctionGut microbiota contributes significantly to brain function by producing neuroactive compounds. These include neuroactive compounds that influence neurotransmitters such as...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
